Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QSP-Based Meropenem Dosing Optimization in Sepsis (Tongji Hospital)
ChiCTR2600131004Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of meropenem in sepsis, sponsored by Tongji Hospital. Primary endpoints: 28-day All-cause Mortality and Meropenem Plasma Concentration. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
meropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2600131004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131004.